Zhang Yunxiao

Dr. Zhang Yunxiao


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2018 in Toxins
Verified
Journal Article
Open access
PDF file
ZYZhang Yunxiao
Zhang Yunxiao
QYQiuchu Yang
Qiuchu Yang
QZQingfeng Zhang
Qingfeng Zhang
DPDezheng Peng
Dezheng Peng
MCMinzhi Chen
Minzhi Chen
ZLZhonghua Liu
Zhonghua Liu
Pain is a medical condition that interferes with normal human life and work and reduces human well-being worldwide. Human voltage-gated sodium channel NaV1.7 (hNaV1.7) is a compelling target that plays a key role in human pain signaling. The 33-residue peptide µ-TRTX-Hhn2b (HNTX-I), a member of NaV-targeting spider toxin (NaSpTx) family 1, has shown negligible activity on mammalian voltage-gated sodium channels (VGSCs), including the hNaV1.7 channel. We engineered analogues of HNTX-I based on sequence conservation in NaSpTx family 1. Substitution of Asn for Ser at position 23 or Asp for His at position 26 conferred potent activity against hNaV1.7. Moreover, multiple site mutations combined together afforded improvements in potency. Ultimately, we generated an analogue E1G–N23S–D26H–L32W with >300-fold improved potency compared with wild-type HNTX-I on hNaV1.7 (IC50 0.036 ± 0.007 µM). Structural simulation suggested that the charged surface and the hydrophobic surface of the modified peptide are responsible for binding affinity to the hNaV1.7 channel, while variable residues may determine pharmacological specificity. Therefore, this study provides a profile for drug design targeting the hNaV1.7 channel.

14 December 2019 in International Journal of Peptide Research and Therapeutics
Verified
Journal Article
Closed access
PDF file
YLYu Liu
Yu Liu
QWQing Wang
Qing Wang
DNDongsong Nie
Dongsong Nie
ZWZhen Wang
Zhen Wang
ZYZhang Yunxiao
Zhang Yunxiao